An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations

– Successfully completed Study IPX203-B16-02

– Able to provide written informed consent prior to the conduct of any study-specific
procedures.

– Female subjects of childbearing potential must have a negative urine pregnancy test at
the baseline visit (Visit 1).

– Agrees to use a medically acceptable method of contraception throughout the study and
for 6 weeks after completing the study.

Exclusion Criteria:

– Intends to use any doses of Rytary® or Duopa™ during this study.

– Plans to use an investigational treatment other than IPX203 during the course of this
study.

– Neurosurgical ablation treatment for PD is planned or anticipated during the study
period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is
permitted during this study.

– Subjects who, in the opinion of the clinical investigator, should not participate in
the study.